[go: up one dir, main page]

MX2023007511A - Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades. - Google Patents

Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades.

Info

Publication number
MX2023007511A
MX2023007511A MX2023007511A MX2023007511A MX2023007511A MX 2023007511 A MX2023007511 A MX 2023007511A MX 2023007511 A MX2023007511 A MX 2023007511A MX 2023007511 A MX2023007511 A MX 2023007511A MX 2023007511 A MX2023007511 A MX 2023007511A
Authority
MX
Mexico
Prior art keywords
disease
imidazo
treatment
pyridine derivatives
irak4 inhibitors
Prior art date
Application number
MX2023007511A
Other languages
English (en)
Inventor
Zhili Xin
Emily Anne Peterson
Ryan Evans
Philippe Bolduc
Magnus Pfaffenbach
Fang Gao
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2023007511A publication Critical patent/MX2023007511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgación se relaciona con derivados de imidazo[1.2-a]piridinilo de fórmula (I), o sales farmacéuticamente aceptables de estos, (ver Fórmula) donde todas las variables son como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. La divulgación proporciona además métodos para su preparación, para su uso médico, en particular para su uso en el tratamiento y manejo de enfermedades o trastornos que incluyen enfermedad inflamatoria, enfermedad autoinmune, cáncer, enfermedad cardiovascular, una enfermedad del sistema nervioso central, enfermedad de la piel, una enfermedad y afección oftálmica y una enfermedad de los huesos.
MX2023007511A 2020-12-22 2021-12-21 Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades. MX2023007511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128964P 2020-12-22 2020-12-22
PCT/US2021/064666 WO2022140425A1 (en) 2020-12-22 2021-12-21 Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease

Publications (1)

Publication Number Publication Date
MX2023007511A true MX2023007511A (es) 2023-09-08

Family

ID=80050991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007511A MX2023007511A (es) 2020-12-22 2021-12-21 Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades.

Country Status (14)

Country Link
US (1) US20240116922A1 (es)
EP (1) EP4267576A1 (es)
JP (1) JP2024501282A (es)
KR (1) KR20230134500A (es)
CN (1) CN116867781A (es)
AR (1) AR124451A1 (es)
AU (1) AU2021409546A1 (es)
CA (1) CA3203129A1 (es)
CO (1) CO2023009316A2 (es)
IL (1) IL303966A (es)
MX (1) MX2023007511A (es)
TW (1) TW202332435A (es)
UY (1) UY39584A (es)
WO (1) WO2022140425A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321236A (zh) * 2021-07-07 2023-06-01 美商百健Ｍａ公司 用於靶向ｉｒａｋ４蛋白降解之化合物
CA3250704A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab IRAK4 INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20220089592A1 (en) * 2019-01-18 2022-03-24 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
PE20220578A1 (es) * 2019-06-27 2022-04-20 Biogen Ma Inc Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
CA3145043A1 (en) * 2019-06-27 2020-12-30 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
AU2021409546A9 (en) 2025-04-10
KR20230134500A (ko) 2023-09-21
AR124451A1 (es) 2023-03-29
JP2024501282A (ja) 2024-01-11
IL303966A (en) 2023-08-01
CN116867781A (zh) 2023-10-10
TW202332435A (zh) 2023-08-16
US20240116922A1 (en) 2024-04-11
EP4267576A1 (en) 2023-11-01
CO2023009316A2 (es) 2023-09-29
UY39584A (es) 2022-07-29
WO2022140425A1 (en) 2022-06-30
AU2021409546A1 (en) 2023-07-06
CA3203129A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CO2022000659A2 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
CO2023009316A2 (es) Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades
ECSP19076732A (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
CR10358A (es) Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos
UY27834A1 (es) Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
MX2017000806A (es) Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos.
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
ECSP045477A (es) COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS.
UY28738A1 (es) Deridos 1h-tieno(2,3-c)pirazol útiles como inhibidores de quinasa
CO2023001509A2 (es) Cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias
CU20230045A7 (es) Compuestos multicíclicos que comprenden estructuras heteroaromáticos o aromáticas bicíclicos útiles como inhibidores de la peptidasa 5 relacionada con calicreína (klk5)
CO2023009313A2 (es) Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades
UY28647A1 (es) Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos
CL2024001748A1 (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
UY40354A (es) Inhibidores de tirosina cinasa 2 y usos de estos
MX2012012531A (es) Derivado de imidazo [1, 2-a] piridina.
PE20231562A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO COMO INHIBIDORES DE IRAK4 Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
MX9304642A (es) Nuevo compuesto.
CO2025015643A2 (es) Derivados de imidazotriazina como moduladores de il-17
UY29043A1 (es) Derivados de diarilmetil piperazina, preparaciones de los mismos y usos de los mismos
SV2007002534A (es) Derivados de (sulfamoil-alquil)- amida de acido heteroaril-carboxilico como inhibidores de factor xa